WhiteOak Capital Balanced Advantage Fund
Regular Plan · IDCW Option · WhiteOak Capital Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +2.97% | +3.13% | 24 of 37 |
| YTD | +1.22% | -2.04% | 5 of 37 |
| INCEPTION | +26.25% | — | — |
Ranked among: Hybrid Scheme - Dynamic Asset Allocation or Balanced Advantage.
NAV History
Portfolio
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 25.37 | 23.81 |
| P/B | 3.11 | 3.28 |
| Price / Sales | 3.78 | 3.13 |
| Price / Cash Flow | 18.27 | 17.27 |
| Dividend Yield (%) | 1.53 | 1.44 |
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
UNIFI DYNAMIC ASSET ALLOCATION FUND
Direct Plan · GROWTH
|
+8.57% | — | — | +8.47% |
|
Mirae Asset Balanced Advantage Fund
Direct Plan · Growth
|
+3.10% | +10.79% | — | +10.95% |
|
ICICI Prudential Balanced Advantage Fund
Regular Plan · Growth
|
+2.77% | +10.67% | +9.66% | +10.93% |
|
Edelweiss Balanced Advantage Fund
Regular Plan · Growth
|
+2.47% | +9.96% | +8.03% | +10.20% |
|
Parag Parikh Dynamic Asset Allocation Fund
Regular Plan · Growth
|
+1.94% | — | — | +5.99% |
|
Bajaj Finserv Balanced Advantage Fund
Direct Plan · Growth
|
+1.44% | — | — | +7.01% |
|
Helios Balanced Advantage Fund
Direct Plan · Growth
|
+1.43% | — | — | +7.10% |
|
Baroda BNP Paribas Balanced Advantage Fund
Regular Plan · Growth Option
|
+1.35% | +11.08% | +9.26% | +12.42% |
|
Axis Balanced Advantage Fund
Direct Plan · Growth Option
|
+1.17% | +12.19% | +9.53% | +9.98% |
|
BANK OF INDIA BALANCED ADVANTAGE FUND
Regular Plan · Growth
|
+1.06% | +8.52% | +9.15% | +7.75% |
More From WhiteOak Capital Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
WhiteOak Capital Pharma and Healthcare Fund
Direct Plan · Growth Option
|
+20.63% | — | — | +22.86% |
|
WhiteOak Capital Special Opportunities Fund
Direct Plan · Growth Option
|
+9.86% | — | — | +16.53% |
|
WhiteOak Capital Arbitrage Fund
Direct Plan · Growth Option
|
+7.12% | — | — | +7.24% |
|
WhiteOak Capital Multi Asset Allocation Fund
Direct Plan · Growth Option
|
+6.82% | +16.01% | — | +15.30% |
|
WhiteOak Capital Mid Cap Fund
Direct Plan · Growth Option
|
+6.44% | +20.80% | — | +21.53% |
|
WhiteOak Capital Liquid Fund
Direct Plan · Growth Option
|
+6.39% | +6.80% | +6.26% | +5.63% |
|
WhiteOak Capital Ultra Short Term Fund
Direct Plan · Growth Option
|
+6.24% | +6.93% | +6.37% | +5.90% |
|
WhiteOak Capital Equity Savings Fund
Direct Plan · Growth Option
|
+5.27% | — | — | +10.73% |
|
WhiteOak Capital Multi Cap Fund
Direct Plan · Growth Option
|
+2.50% | +18.14% | — | +17.57% |
|
WhiteOak Capital Balanced Hybrid Fund
Direct Plan · Growth Option
|
+1.54% | +11.10% | — | +11.27% |
About This Scheme
Investment Objective
The primary objective of the Scheme is to provide long term capital appreciation and generate income from a dynamically managed portfolio of equity & equity related instruments and debt & money market securities. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity and Equity Related Instruments (including REITs): 0% - 100%; Debt Securities (including securitized debt) and Money Market Instruments, cash, and cash equivalents and / or units of domestic liquid mutual fund schemes: 0% - 100%
Exit Load
Nil
Fund Managers
FM1 - Mr. Ramesh Mantri; FM2- Mr. Piyush Baranwal; FM3 - Ms. Trupti Agrawal; FM4 - Mr. Dheeresh Pathak; FM5 - Mr. Ashish Agrawal
FM1 - Comanage/Equity; FM2 - Comanage/Debt; FM3 - Assistant Fund Manager - Equity; FM4 - Assistant Fund Manager - Equity; FM5 - Fund Manager - Arbitrage Transactions
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.
GMP IPO Watch